Swiss drug authority Swissmedic has begun evaluating the so-called “Covid-19 Vaccine AstraZeneca”. It is the first time that a drugmaker has presented a coronavirus vaccine for approval in Switzerland.
AstraZeneca, which developed the vaccine in collaboration with the University of Oxford, submitted its application to Swissmedic at the start of this month.
The vaccine’s scientific evaluation will be done via a “rolling submission” process. This allows a pharmaceutical company to launch the application procedure before a product’s development is complete.
This “enables Swissmedic to carry out the scientific assessment of non-clinical data from laboratory tests while clinical trials are still in progress,” announced Swissmedic in a statement on Tuesday, noting that trial results must be submitted for scientific review as they become available over the next weeks and months.
More
More
Half of Swiss would get vaccinated against Covid-19
This content was published on
If there were an efficient vaccination against coronavirus, every second person in Switzerland would take it, says a survey.
“However, no decision on authorisation can be taken until all the data needed to assess the safety, quality and efficacy of the vaccine have been submitted. The documentation must demonstrate how safe and effective the vaccine is in protecting humans against the new SARS-CoV-2 coronavirus,” wrote the Swiss drug authority.
Swissmedic noted that while it is reviewing the vaccine independently, it is also working closely with partner authorities abroad. No medicinal product can go onto the Swiss market without Swissmedic’s approval.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
Swiss authorities announce cost-cutting in asylum sector
This content was published on
The government notably wants to improve integration into the labour force, particularly for people with protection status S.
Various leaders confirm participation at Ukraine peace conference
This content was published on
The presidents of Poland, Finland, and Latvia and the prime ministers of Spain and Belgium will be at the Swiss-hosted talks in mid-June.
This content was published on
In the winter season up to April 2024, railway and cable car operators ferried 3% more visitors compared to the previous winter, and 5% more than the five-year average.
Rhine flooding: Swiss to invest CHF1 billion with Austria
This content was published on
As part of an international agreement with Austria, the Swiss government wants to pump CHF1 billion ($1.1 billion) into flood protection measures along the Rhine over the next three decades.
Swiss government proposes CHF10 million UNRWA donation
This content was published on
After months of debate, Switzerland plans to give CHF10 million ($11 million) to the UN agency this year, rather than the CHF20 million initially foreseen.
Swiss study: insects mainly migrate at midday and dusk
This content was published on
A study led by the Swiss Ornithological Institute in canton Lucerne is helping to better understand the movement patterns of migratory insects.
Red Cross: 22 staff killed in Middle East since October
This content was published on
The Red Cross and Red Crescent network in Gaza and Israel has lost 22 staff members since last October, the Swiss Red Cross (SRC) said on Wednesday.
Switzerland pre-orders 4.5 million doses of Covid-19 vaccine
This content was published on
The Swiss government has signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of a Covid-19 vaccine currently in development.
Switzerland fast-tracks antiviral medication against Covid-19
This content was published on
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday. It can now be used for a limited period of time to…
Join the conversation!